Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has initiated a Phase II study evaluating satraplatin in combination with the steroid, prednisone, in patients with metastatic hormone-refractory prostate cancer who previously have been treated with docetaxel. The study is being sponsored by the US National Cancer Institute.
Subscribe to our email newsletter
The trial is a single-arm study with a planned enrollment of 66 patients with metastatic hormone-refractory prostate cancer who have been previously treated with docetaxel therapy and with no more than one other previous cytotoxic chemotherapy regimen.
The primary objective of the trial is to determine if the presence of certain variants of the gene, ERCC1, affects progression-free survival in this patient population. ERCC1 is involved in DNA damage repair. Satraplatin, like other platinum agents, has been shown to work via targeting the DNA in tumor cells.
Martine George, chief medical officer of GPC Biotech, said: “The results of this trial may provide important information in determining which hormone-refractory prostate cancer patients are more likely to benefit from treatment with satraplatin.”